Within a day of testing positive for covid-19 in June, Miranda Kelly was sick enough to be scared. At 44, with diabetes and high blood pressure, Kelly, a certified nursing assistant, was having trouble breathing, symptoms serious enough to send her to the emergency room.
When her husband, Joe, 46, fell ill with the virus, too, she really got worried, especially about their five teenagers at home: “I thought, ‘I hope to God we don’t wind up on ventilators. We have children. Who’s going to raise these kids?”
But the Kellys, who live in Seattle, had agreed just after their diagnoses to join a clinical trial at the nearby Fred Hutch cancer research center that’s part of an international effort to test an antiviral treatment that could halt covid early in its course.
By the next day, the couple were taking four pills, twice a day. Though they weren’t told whether they had received an active medication or placebo, within a week, they said, their symptoms were better. Within two weeks, they had recovered.
“I don’t know if we got the treatment, but I kind of feel like we did,” Miranda Kelly said. “To have all these underlying conditions, I felt like the recovery was very quick.”
The Kellys have a role in developing what could be the world’s next chance to thwart covid: a short-term regimen of daily pills that can fight the virus early after diagnosis and conceivably prevent symptoms from developing after exposure.
“Oral antivirals have the potential to not only curtail the duration of one’s covid-19 syndrome, but also have the potential to limit transmission to people in your household if you are sick,” said Timothy Sheahan, a virologist at the University of North Carolina-Chapel Hill who has helped pioneer these therapies.
Antivirals are already essential treatments for other viral infections, including hepatitis C and HIV. One of the best known is Tamiflu, the widely prescribed pill that can shorten the duration of influenza and reduce the risk of hospitalization if given quickly.
The medications, developed to treat and prevent viral infections in people and animals, work differently depending on the type. But they can be engineered to boost the immune system to fight infection, block receptors so viruses can’t enter healthy cells, or lower the amount of active virus in the body.
At least three promising antivirals for covid are being tested in clinical trials, with results expected as soon as late fall or winter, said Carl Dieffenbach, director of the Division of AIDS at the National Institute of Allergy and Infectious Diseases, who is overseeing antiviral development.
“I think that we will have answers as to what these pills are capable of within the next several months,” Dieffenbach said.
The top contender is a medication from Merck & Co. and Ridgeback Biotherapeutics called molnupiravir, Dieffenbach said. This is the product being tested in the Kellys’ Seattle trial. Two others include a candidate from Pfizer, known as PF-07321332, and AT-527, an antiviral produced by Roche and Atea Pharmaceuticals.
They work by interfering with the virus’s ability to replicate in human cells. In the case of molnupiravir, the enzyme that copies the viral genetic material is forced to make so many mistakes that the virus can’t reproduce. That, in turn, reduces the patient’s viral load, shortening infection time and preventing the kind of dangerous immune response that can cause serious illness or death.
So far, only one antiviral drug, remdesivir, has been approved to treat covid. But it is given intravenously to patients ill enough to be hospitalized, and is not intended for early, widespread use. By contrast, the top contenders under study can be packaged as pills.
Clinical trials have followed, including an early trial of 202 participants last spring that showed that molnupiravir rapidly reduced the levels of infectious virus. Merck chief executive Robert Davis said this month that the company expects data from its larger phase 3 trials in the coming weeks, with the potential to seek emergency use authorization from the Food and Drug Administration “before year-end.”
Scientists from the Terasaki Institute for Biomedical Innovation (TIBI) have developed a contact lens that can capture and detect exosomes, nanometer-sized vesicles found in bodily secretions which have the potential for being diagnostic cancer [...]
Among the total number of deaths caused by different types of cancer, esophageal cancer is the sixth most significant. Several conventional treatments, such as radiotherapy, chemotherapy, and surgery have multiple side effects, including off-target [...]
Cell membrane-coated nanoparticles, applied in targeted drug delivery strategies, combine the intrinsic advantages of synthetic nanoparticles and cell membranes. Although stem cell-based delivery systems were highlighted for their targeting capability in tumor therapy, inappropriate [...]
When babies in the African countries of Guinea Bissau and Uganda were given the tuberculosis vaccine, something remarkable happened. Instead of the vaccine only protecting against the target bacteria – Myocbacterium tuberculosis – the tuberculosis vaccine offered broad protection against a [...]
Thousands of years ago, across the Eastern Mediterranean, multiple Bronze Age civilizations took a distinct turn for the worse at around the same time. The Old Kingdom of Egypt and the Akkadian Empire both collapsed, and there was [...]
IN OCTOBER 2014, virologist Edward Holmes took a tour of the Huanan Seafood Wholesale Market in Wuhan, a once relatively overlooked city of about 11 million people in the central Chinese province of Hubei. The market would [...]
Self-healable ionic sensing materials with fatigue resistance are imperative in robotics and soft electronics for extended service life. The existing artificial ionic skins with self-healing capacity were prepared by network reconfiguration, constituting low-energy amorphous [...]
As demand for solar energy rises around the world, scientists are working to improve the performance of solar devices—important if the technology is to compete with traditional fuels. But researchers face theoretical limits on [...]
When shrimp shell nanoparticles were mixed into cement paste, the material became substantially stronger — researchers propose an innovation that could lead to less seafood waste and fewer carbon dioxide emissions from concrete production. [...]
A black-and-white video shared on social media showed a microscopic corkscrew-shaped helix as it appeared to consume a sperm, transport it, and ultimately lead the little swimmer into the wall of an [...]
Polymers containing quantum dots (QDs) are considered crucial components of next-generation consumer items, but ambiguity remains regarding how these compounds may negatively affect public health and the environment. A pre-proof paper from the Journal of Hazardous [...]
A new copper coating that kills bacteria quicker and in greater amounts than current formulations could soon be available for hospitals and other high-traffic facilities. Although current formulations made of pure copper are antibacterial [...]
A vaccination as tumor therapy - with a vaccine individually created from a patient's tissue sample that " attaches" the body's own immune system to cancer cells: the basis for this long-term vision has [...]
Although retinoic acid (RA) can induce cell death, its weak anticancer efficacy limits its clinical applications. To this end, stimulus-responsive self-assembling prodrug-based nanomedicines are promising candidates that enable controlled drug delivery. In an article [...]
Graphene is a multifunctional carbon nanomaterial widely synthesized for its applications in composites, energy storage, and sensors. Although previous reviews mentioned that achieving an increased yield compromises graphene quality, limiting its commercialization, recent research [...]
A new COVID variant has recently been detected in several countries including the UK, US, India, Australia and Germany. Called BA.2.75, it’s a subvariant of omicron. You might have also heard it called “Centaurus”, the [...]